Patent ID: 7951575
Filing Date: 2011-05-31
Classification: A23K,A23L,A61K,A61P,C12N,Y10S

Abstract:
1. A phage preparation comprising a broad host range isolated phage selected from the Myoviridae family having a genome size of 170 kb and lytic activity against pathogenic E. coli or Salmonella strains, wherein the isolated phage is virulent and safe to administer to a human or animal, wherein the isolated phage is an obligate virulent phage with a contractile tail, and wherein the isolated phage is incorporated into a product selected from the group consisting of a food product, a pharmaceutical product, a nutritional supplement and a composition for oral administration, wherein the isolated phage is selected from the group consisting of NCC-JS4 (CNCM I-2763), NCC-JS35 (CNCM I-2764), NCC-JS1.4 (CNCM I-2765), and NCC-JSF (CNCM I-2766).